Phio Pharmaceuticals Corp. Contracts & Agreements

Form of Series E Common Stock Warrant, dated December 20, 2024 (Filed With SEC on December 20, 2024)

Form of Placement Agent Warrant, dated December 20, 2024 (Filed With SEC on December 20, 2024)

Form of Securities Purchase Agreement, dated December 19, 2024, by and between the Company and each of the Purchasers signatory thereto (Filed With SEC on December 20, 2024)

Offer Letter, executed July 16, 2024, by and between the Company and Robert M. Infarinato (Filed With SEC on August 1, 2024)

Form of Series C/D Warrant, dated July 12, 2024 (Filed With SEC on July 12, 2024)

Form of Placement Agent Warrant, dated July 12, 2024 (Filed With SEC on July 12, 2024)

Form of Inducement Letter Agreement, dated July 12, 2024, by and between Phio Pharmaceuticals Corp. and the Holders (Filed With SEC on July 12, 2024)

2020 Phio Pharmaceuticals Corp. Long Term Incentive Plan, as amended and restated (Filed With SEC on June 21, 2024)

Purchase Agreement, dated May 16, 2024, by and between Phio Pharmaceuticals Corp. and Triton Funds LP (Filed With SEC on May 17, 2024)

Description of Securities Registered Pursuant to Section 12(b) of the Securities Exchange Act of 1934 (Filed With SEC on April 1, 2024)

Form of Series A/B Warrant, dated December 8, 2023 (Filed With SEC on December 8, 2023)

Form of Placement Agent Warrant, dated December 8, 2023 (Filed With SEC on December 8, 2023)

Form of Inducement Letter Agreement, dated December 6, 2023, by and between Phio Pharmaceuticals Corp. and the Holders (Filed With SEC on December 8, 2023)

2020 Phio Pharmaceuticals Corp. Long Term Incentive Plan, as amended and restated (Filed With SEC on November 9, 2023)

Form of Nonqualified Stock Option Award under the Companys 2020 Long Term Incentive Plan (Filed With SEC on November 9, 2023)

2020 Phio Pharmaceuticals Corp. Long Term Incentive Plan, as amended and restated (Filed With SEC on July 26, 2023)

Form of Series A Common Stock Warrant, dated June 2, 2023 (Filed With SEC on June 2, 2023)

Form of Series B Common Stock Warrant, dated June 2, 2023 (Filed With SEC on June 2, 2023)

Form of Pre-funded Common Stock Warrant, dated June 2, 2023 (Filed With SEC on June 2, 2023)

Form of Securities Purchase Agreement, dated May 31, 2023, by and between the Company and each of the Purchasers signatory thereto (Registered Direct Offering) (Filed With SEC on June 2, 2023)

Form of Securities Purchase Agreement, dated May 31, 2023, by and between the Company and each of the Purchasers signatory thereto (PIPE Private Placement) (Filed With SEC on June 2, 2023)

Form of Registration Rights Agreement, dated May 31, 2023, by and between the Company and each of the Purchasers signatory thereto (Filed With SEC on June 2, 2023)

Form of Series A Common Stock Warrant, dated April 20, 2023 (Filed With SEC on April 20, 2023)

Form of Series B Common Stock Warrant, dated April 20, 2023 (Filed With SEC on April 20, 2023)

Form of Existing Warrant Amendment, dated April 18, 2023 (Filed With SEC on April 20, 2023)

Form of Securities Purchase Agreement, dated April 18, 2023, by and between the Company and each of the Purchasers signatory thereto (Filed With SEC on April 20, 2023)

Clinical Co-development Agreement, dated February 26, 2021, by and between Phio Pharmaceuticals Corp. and AgonOx, Inc (Filed With SEC on March 22, 2023)

Separation Agreement, date May 5, 2022, by and between Phio Pharmaceuticals Corp. and Gerrit Dispersyn, Dr. Med. Sc (Filed With SEC on March 22, 2023)

Employment Agreement, dated February 20, 2023, by and between the Company and Robert J. Bitterman (Filed With SEC on February 22, 2023)

Subscription and Investment Representation Agreement, dated November 16, 2022, by and between Phio Pharmaceuticals Corp. and the purchaser signatory thereto (Filed With SEC on November 16, 2022)

Form of Restricted Stock Unit Award under the Companys 2020 Long Term Incentive Plan (Filed With SEC on March 25, 2021)

Form of Placement Agent Warrant (Filed With SEC on February 17, 2021)

Form of Securities Purchase Agreement, dated February 12, 2021, by and between the Company and the Purchasers signatory therein (Filed With SEC on February 17, 2021)

Form of Common Stock Warrant (Filed With SEC on January 25, 2021)

Form of Pre-Funded Common Stock Warrant (Filed With SEC on January 25, 2021)

Form of Securities Purchase Agreement, dated January 21, 2021, by and between the Company and the Purchasers signatory therein (Filed With SEC on January 25, 2021)

Form of Registration Rights Agreement, dated January 21, 2021, by and between the Company and the Purchasers signatory therein (Filed With SEC on January 25, 2021)

Form of Common Stock Warrant (Filed With SEC on April 2, 2020)

Securities Purchase Agreement, dated March 31, 2020, by and between the Company and the Purchasers signatory therein (Filed With SEC on April 2, 2020)

Description of Securities Registered Pursuant to Section 12(b) of the Securities Exchange Act of 1934 (Filed With SEC on March 26, 2020)

Underwriting Agreement, dated as of February 11, 2020, between Phio Pharmaceuticals Corp. and H.C. Wainwright & Co., LLC, as representative of the underwriters named therein (Filed With SEC on February 13, 2020)

Form of Common Stock Purchase Warrant (Filed With SEC on February 13, 2020)

Form of Pre-Funded Common Stock Purchase Warrant (Filed With SEC on February 13, 2020)

Form of Underwriter Common Stock Purchase Warrant (Filed With SEC on February 13, 2020)

Form of Common Stock Warrant (Filed With SEC on February 6, 2020)

Securities Purchase Agreement, dated February 4, 2020, by and between the Company and the Purchasers signatory therein (Filed With SEC on February 6, 2020)

Form of Underwriting Agreement (Filed With SEC on January 31, 2020)

Form of Warrant (Filed With SEC on January 31, 2020)

Form of Pre-Funded Warrant (Filed With SEC on January 31, 2020)

Form of Underwriter Warrant (Filed With SEC on January 31, 2020)

Placement Agency Agreement, by and between Phio Pharmaceuticals Corp. and H.C. Wainwright & Co., LLC dated as of November 18, 2019 (Filed With SEC on November 20, 2019)

Form of Placement Agent Warrants of Phio Pharmaceuticals Corp (Filed With SEC on November 20, 2019)

Phio Pharmaceuticals Corp. 2012 Long Term Incentive Plan (Filed With SEC on November 12, 2019)

First Amendment to Purchase Agreement by and between Phio Pharmaceuticals Corp. and Lincoln Park Capital Fund, LLC (Filed With SEC on August 30, 2019)

Purchase Agreement, dated as of August 7, 2019 by and between Phio Pharmaceuticals Corp. and Lincoln Park Capital Fund, LLC (Filed With SEC on August 9, 2019)

Registration Rights Agreement, dated as of August 7, 2019, by and between Phio Pharmaceuticals Corp. and Lincoln Park Capital Fund, LLC (Filed With SEC on August 9, 2019)

Employment Agreement, dated April 22, 2019, between Phio Pharmaceuticals Corp. and John A. Barrett, Ph.D (Filed With SEC on May 14, 2019)

Amendment No. 2 to Cauwenbergh Non-Plan Stock Compensation Election Agreement (Filed With SEC on February 15, 2019)

First Amendment to Lease Dated January 22, 2019 (Filed With SEC on January 28, 2019)

Amendment No. 1 to Cauwenbergh Non-Plan Stock Compensation Election Agreement (Filed With SEC on December 21, 2018)

Underwriting Agreement, dated as of October 1, 2018, between RXi Pharmaceuticals Corporation and H.C. Wainwright & Co., LLC, as representative of the underwriters named therein (Filed With SEC on October 5, 2018)

Form of Underwriter Warrant (Filed With SEC on October 5, 2018)

Form of Underwriting Agreement (Filed With SEC on September 28, 2018)

Form of Warrant (Filed With SEC on September 28, 2018)

Form of Pre-Funded Warrant (Filed With SEC on September 28, 2018)

Non-Plan Stock Compensation Election and Terms and Conditions (Filed With SEC on September 4, 2018)

Form of Warrant (Filed With SEC on April 11, 2018)

Form of Placement Agent Warrant (Filed With SEC on April 11, 2018)

Securities Purchase Agreement, dated April 9, 2018, by and between the Company and the Purchasers listed therein (Filed With SEC on April 11, 2018)

PURCHASE AGREEMENT (Filed With SEC on August 18, 2017)

PURCHASE AGREEMENT (Filed With SEC on August 9, 2017)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on August 9, 2017)

EMPLOYMENT AGREEMENT (Filed With SEC on March 30, 2017)

NON-COMPETITION AGREEMENT (Filed With SEC on March 30, 2017)

STOCK PURCHASE AGREEMENT (Filed With SEC on January 10, 2017)

2,131,111 SHARES OF COMMON STOCK, 8,082 SHARES OF SERIES B CONVERTIBLE PREFERRED STOCK (CONVERTIBLE INTO 8,980,000 SHARES OF COMMON STOCK) AND WARRANTS (EXERCISABLE FOR 11,111,111... (Filed With SEC on December 19, 2016)

SHARES OF COMMON STOCK, SHARES OF SERIES BCONVERTIBLE PREFERRED STOCK (CONVERTIBLE INTO SHARES OF COMMON STOCK) AND WARRANTS (EXERCISABLE FOR SHARES OFCOMMON STOCK) OF RXi... (Filed With SEC on December 14, 2016)

COMMON STOCK PURCHASE WARRANT RXi PHARMACEUTICALS CORPORATION (Filed With SEC on December 14, 2016)

SHARES OF COMMON STOCK, SHARES OF SERIES BCONVERTIBLE PREFERRED STOCK (CONVERTIBLE INTO SHARES OF COMMON STOCK) AND WARRANTS (EXERCISABLE FOR SHARES OFCOMMON STOCK) OF RXi... (Filed With SEC on November 30, 2016)

COMMON STOCK PURCHASE WARRANT RXi PHARMACEUTICALS CORPORATION (Filed With SEC on November 30, 2016)

OVERALLOTMENT COMMON STOCK PURCHASE RIGHT RXI PHARMACEUTICALS CORPORATION (Filed With SEC on May 21, 2015)

COMMON STOCK PURCHASE WARRANT RXI PHARMACEUTICALS CORPORATION (Filed With SEC on May 21, 2015)

430 Park Avenue | New York, New York 10022 | 212 ###-###-#### | www.hcwco.com Member: FINRA/SIPC 1 (Filed With SEC on May 21, 2015)

RXI PHARMACEUTICALS CORPORATION SECURITIES PURCHASE AGREEMENT (Filed With SEC on May 21, 2015)

PURCHASE AGREEMENT (Filed With SEC on December 19, 2014)

PURCHASE AGREEMENT (Filed With SEC on April 23, 2014)

MANUFACTURING AND DISTRIBUTION AGREEMENT (Filed With SEC on March 28, 2014)

LEASE AGREEMENT (Filed With SEC on December 20, 2013)

RXI PHARMACEUTICALS CORPORATION 2012 LONG TERM INCENTIVE PLAN INCENTIVE STOCK OPTION AGREEMENT (Filed With SEC on September 18, 2013)

RXI PHARMACEUTICALS CORPORATION 2012 LONG TERM INCENTIVE PLAN NON-STATUTORY STOCK OPTION AGREEMENT (Filed With SEC on September 18, 2013)

Amendment to RXi Pharmaceuticals Corporation 2012 Incentive Plan (Filed With SEC on September 18, 2013)

RXi PHARMACEUTICALS CORPORATION EMPLOYEE STOCK PURCHASE PLAN (Filed With SEC on September 18, 2013)

ASSET PURCHASE AGREEMENT (Filed With SEC on May 15, 2013)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on March 7, 2013)

LEASE TENANT: RXI PHARMACEUTICALS AND LANDLORD:WESTBOROUGH OFFICE PARK BUILDING FIVE LP 1500 West Park Drive Westborough, Massachusetts TABLE OF CONTENTS (Filed With SEC on July 3, 2012)

SUBLEASE BETWEEN MASSACHUSETTS BIOMEDICAL INITIATIVES, INC. (MBI) AS SUB-LANDLORD AND RXi Pharmaceuticals, Corp. AS SUB-TENANT AT Gateway Park, 60 Prescott Street, Worcester, MA... (Filed With SEC on July 3, 2012)

OMNIBUS AMENDMENT (Filed With SEC on May 14, 2012)

SECOND OMNIBUS AMENDMENT (Filed With SEC on May 14, 2012)

THIRD OMNIBUS AMENDMENT (Filed With SEC on May 14, 2012)

FOURTH OMNIBUS AMENDMENT (Filed With SEC on May 14, 2012)

FIFTH OMNIBUS AMENDMENT (Filed With SEC on May 14, 2012)

SIXTH OMNIBUS AMENDMENT (Filed With SEC on May 14, 2012)

SEVENTH AMENDMENT AGREEMENT (Filed With SEC on May 14, 2012)

EMPLOYMENT AGREEMENT (Filed With SEC on May 3, 2012)

We are currently working towards filing an investigational new drug application (IND) for RXI-109 and initiating a Phase I/II clinical trial in 2012 (Filed With SEC on February 7, 2012)

We are currently working towards filing an investigational new drug application (IND) for RXI-109 and initiating a Phase I/II clinical trial in 2012 (Filed With SEC on January 23, 2012)

We are currently working towards filing an investigational new drug application (IND) for RXI-109 and initiating a Phase I/II clinical trial in 2012 (Filed With SEC on December 29, 2011)

We are currently working towards filing an investigational new drug application (IND) for RXI-109 and initiating a Phase I/II clinical trial in 2012 (Filed With SEC on December 8, 2011)

We are currently working towards filing an investigational new drug application (IND) for RXI-109 and initiating a Phase I/II clinical trial in 2012 (Filed With SEC on October 25, 2011)

Category

Industry

Companies

Contracts

Phio Pharmaceuticals Corp. Contracts & Agreements